Výsledky vyhledávání

P101 Outcomes with mepolizumab and benralizumab in severe eosinophilic asthma

Autor: D Allen, CT Pantin, G Tavernier, K Hince, Stephen J. Fowler, Robert Niven, P Aspin, L Elsey

Publikováno v: Emerging evidence on the use of biological agents in severe asthma.

Introduction Benralizumab and mepolizumab are subcutaneous monoclonal antibodies licensed for the treatment of severe eosinophilic asthma. Benralizumab acts by blocking the anti-IL5 α receptor whilst mepolizumab binds to IL-5 inhibiting it binding t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a317134d20e812d9338d85c18c65c10
https://doi.org/10.1136/thorax-2020-btsabstracts.246

Zobrazit plný text záznamu

P93 Response to reslizumab in severe asthma patients unresponsive to mepolizumab or with suspected vasculitis

Autor: R Waye, N Thomas, T Pantin, K Hince, Stephen J. Fowler, D Allen, L Elsey, Robert Niven, B Hama, LJ Holmes, G Tavernier

Publikováno v: Biologics in asthma.

Introduction Reslizumab is the second biologic available targeting Interleukin 5 (IL5), for the management of severe eosinophilic asthma. We use it in patients who have failed to respond to mepolizumab or with suspected vasculitis. Aims To determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::131bf9aeaea453bb1a5ec39feb068efa
https://doi.org/10.1136/thorax-2019-btsabstracts2019.236

Zobrazit plný text záznamu

P13 Bronchial thermoplasty maintains a long-term reduction in peripheral blood eosinophils in severe asthma

Autor: LJ Holmes, K Hince, Robert Niven, G McCumesky, D Ryan

Publikováno v: Asthma: airways and antibodies.

Introduction Severe Asthma, characterised by persistent symptoms despite maximal medical therapy, represents 5% of asthma cases. Bronchial Thermoplasty (BT) is a novel therapy where radiofrequency thermal energy is applied to airways distal to the ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ec25771208af30af22d7cbe34f03f92
https://doi.org/10.1136/thoraxjnl-2017-210983.155

Zobrazit plný text záznamu

Audit of bronchial thermoplasty patients who did not complete their treatment session as planned

Autor: C. Ustabasi, G McCumesky, Robert Niven, K Hince, LJ Holmes, D Ryan

Publikováno v: 5.1 Airway Pharmacology and Treatment.

The Manchester Severe Asthma Service had planned 37 patients for Bronchial Thermoplasty (BT), under conscious sedation to complete three therapy sessions. Of these 2 (5%) were identified at first session, as part of a routine diagnostic assessment be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd570cc5e5700748034dc13518407e1c
https://doi.org/10.1183/13993003.congress-2016.pa4121

Zobrazit plný text záznamu

S54 CPAP reduces exacerbations in tracheobronchomalacia

Autor: K Hince, D Jones, M Demirbag, G Tavernier, Stephen J. Fowler, TB Morris, C Ustabasi

Publikováno v: Thorax. 71:A32.2-A33

Overview Tracheobronchomalacia (TBM) is increasingly recognised as a significant diagnosis in patients diagnosed with “severe asthma”. Continuous Positive Airway Pressure (CPAP) is used as first line treatment to stent the airway in TBM patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::001727027e30ef9df3dd7758f5aa35b8
https://doi.org/10.1136/thoraxjnl-2016-209333.60

Zobrazit plný text záznamu

P159 The use of omalizumab in severe asthma is associated with a decline in blood eosinophils

Autor: K Hince, Robert Niven, G Tavernier, Stephen J. Fowler, LJ Holmes

Publikováno v: Thorax. 70:A157.1-A157

Introduction/aim Omalizumab (Xolair) is a recombinant humanised monoclonal antibody licensed for the treatment of severe allergic asthma patients with IgE mediated disease. The mechanism of action of omalizumab is to bind to IgE preventing interactio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54f72fa49ac2120505a5d68233a1db28
https://doi.org/10.1136/thoraxjnl-2015-207770.296

Zobrazit plný text záznamu

P73 A pilot study to investigate the use of serum inhaled corticosteroid concentration as a potential marker of treatment adherence in severe asthma

Autor: Brian G. Keevil, Stephen J. Fowler, D Ryan, G Tavernier, K Hince, KE George, Robert Niven

Publikováno v: Thorax. 70:A112.1-A112

Background Inhaled anti-inflammatory therapy is fundamental to asthma management, but adherence is very poor. This increases the risk of exacerbations and poor symptom control. Currently there is no direct way of assessing adherence to inhaled steroi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6849e16fe83c57d43dad77c8a77ff7d
https://doi.org/10.1136/thoraxjnl-2015-207770.210

Zobrazit plný text záznamu

S96 Bronchial Thermoplasty Reduces Peripheral Blood Eosinophils In Severe Asthma Demonstrating Systemic Effects Of A Localised Therapy

Autor: Stephen J. Fowler, G Tavernier, D Ryan, R Daly, Robert Niven, K Hince, LJ Holmes, G McCumesky

Publikováno v: Thorax. 69:A52-A52

Introduction Severe Asthma, characterised by persistent symptoms despite maximal medical therapy, represents 5% of asthma cases. Bronchial Thermoplasty (BT) is a novel therapy, NICE approved for Severe Asthma patients uncontrolled despite step 4/5 of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a6dc7dbab72115fd55f082cce7a5e73
https://doi.org/10.1136/thoraxjnl-2014-206260.102

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání